Floatz logo

Adebrelimab

VEGFR-TKI

Federation Francophone de Cancerologie DigestiveN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the VEGFR-TKI cohort.

Asset / SponsorPhaseRating
Fruquintinib
Federation Francophone de Cancerologie Digestive
N/AD

Same molecule, other indications

Adebrelimab is also rated in:

Metastatic Colon CancerDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
67 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →